ATE493411T1 - Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer - Google Patents

Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer

Info

Publication number: ATE493411T1
Authority: AT; Austria
Prior art keywords: pyrroloä2; büpyridine; benzenesulfonamide compounds; ikk2 inhibitors; ikk2
Prior art date: 2006-09-22

Application number

AT07820377T

Other languages

English (en)

Inventor

Paul Bamborough

Michael Barker

Sebastien Campos

Richard COUSINS

Paul Faulder

Heather Hobbs

Duncan Holmes

Michael Johnston

John Liddle

Jeremy Payne

John Pritchard

Caroline Whitworth

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-22

Filing date

2007-09-20

Publication date

2011-01-15

2006-09-22 Priority claimed from GB0618776A external-priority patent/GB0618776D0/en

2007-03-01 Priority claimed from GB0704012A external-priority patent/GB0704012D0/en

2007-09-04 Priority claimed from GB0717170A external-priority patent/GB0717170D0/en

2007-09-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE493411T1 publication Critical patent/ATE493411T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

AT07820377T 2006-09-22 2007-09-20 Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer ATE493411T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0618776A GB0618776D0 (en)	2006-09-22	2006-09-22	Novel compounds
GB0704012A GB0704012D0 (en)	2007-03-01	2007-03-01	Novel compounds
GB0717170A GB0717170D0 (en)	2007-09-04	2007-09-04	Novelcompounds
PCT/EP2007/059933 WO2008034860A1 (en)	2006-09-22	2007-09-20	Pyrrolo[2, 3-b]pyridin-4-yl-benzenesulfonamide compounds as ikk2 inhibitors

Publications (1)

Publication Number	Publication Date
ATE493411T1 true ATE493411T1 (de)	2011-01-15

Family

ID=39092148

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07820377T ATE493411T1 (de)	2006-09-22	2007-09-20	Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer

Country Status (11)

Country	Link
US (3)	US20100035917A1 (de)
EP (1)	EP2069341B1 (de)
JP (1)	JP2010504301A (de)
AR (1)	AR062928A1 (de)
AT (1)	ATE493411T1 (de)
CL (1)	CL2007002708A1 (de)
DE (1)	DE602007011645D1 (de)
PE (1)	PE20080925A1 (de)
TW (1)	TW200836724A (de)
UY (1)	UY30600A1 (de)
WO (1)	WO2008034860A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0400895D0 (en) *	2004-01-15	2004-02-18	Smithkline Beecham Corp	Chemical compounds
AR050253A1 (es) *	2004-06-24	2006-10-11	Smithkline Beecham Corp	Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
GB0804592D0 (en) *	2008-03-12	2008-04-16	Glaxo Group Ltd	Novel compounds
GB0804591D0 (en) *	2008-03-12	2008-04-16	Glaxo Group Ltd	Novel compounds
US8642069B2 (en) *	2008-08-27	2014-02-04	Alexander D. Goldin	Composition and method for treating colds
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
JP2014516084A (ja) *	2011-06-10	2014-07-07	グラクソスミスクライン、インテレクチュアル、プロパティー、リミテッド	新規化合物
EP3822273B1 (de)	2012-06-13	2024-04-10	Incyte Holdings Corporation	Substituierte tricyclische verbindungen als fgfr-inhibitoren
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
TW201444836A (zh) *	2013-03-14	2014-12-01	Abbvie Inc	吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
AR101528A1 (es) *	2013-03-14	2016-12-28	Abbvie Inc	Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
SG10201708520YA (en)	2013-04-19	2017-12-28	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MX2017010673A (es)	2015-02-20	2018-03-21	Incyte Corp	Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112867716A (zh)	2018-05-04	2021-05-28	因赛特公司	Fgfr抑制剂的固体形式和其制备方法
CN112566912A (zh)	2018-05-04	2021-03-26	因赛特公司	Fgfr抑制剂的盐
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en)	2019-10-14	2022-04-21	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
KR20220131900A (ko)	2019-12-04	2022-09-29	인사이트 코포레이션	Fgfr 억제제의 유도체
EP4069696A1 (de)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclische heterocyclen als fgfr-inhibitoren
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
CN114210133B (zh) *	2021-12-13	2023-01-24	广德辉龙环保科技有限公司	一种抗紫外线过滤袋及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1427707A1 (de) *	2001-09-19	2004-06-16	Pharmacia Corporation	Substituierte indazol verbindungen zur behandlung von entzündungen
GB0308466D0 (en) *	2003-04-11	2003-05-21	Novartis Ag	Organic compounds

2007
- 2007-09-20 JP JP2009528719A patent/JP2010504301A/ja active Pending
- 2007-09-20 TW TW096135178A patent/TW200836724A/zh unknown
- 2007-09-20 AR ARP070104169A patent/AR062928A1/es not_active Application Discontinuation
- 2007-09-20 US US12/442,012 patent/US20100035917A1/en not_active Abandoned
- 2007-09-20 US US11/858,143 patent/US20080146606A1/en not_active Abandoned
- 2007-09-20 UY UY30600A patent/UY30600A1/es unknown
- 2007-09-20 CL CL200702708A patent/CL2007002708A1/es unknown
- 2007-09-20 WO PCT/EP2007/059933 patent/WO2008034860A1/en active Application Filing
- 2007-09-20 US US11/858,144 patent/US20080176891A1/en not_active Abandoned
- 2007-09-20 PE PE2007001270A patent/PE20080925A1/es not_active Application Discontinuation
- 2007-09-20 AT AT07820377T patent/ATE493411T1/de not_active IP Right Cessation
- 2007-09-20 EP EP07820377A patent/EP2069341B1/de active Active
- 2007-09-20 DE DE602007011645T patent/DE602007011645D1/de active Active

Also Published As

Publication number	Publication date
CL2007002708A1 (es)	2008-04-04
AR062928A1 (es)	2008-12-17
EP2069341A1 (de)	2009-06-17
EP2069341B1 (de)	2010-12-29
WO2008034860A1 (en)	2008-03-27
US20080146606A1 (en)	2008-06-19
TW200836724A (en)	2008-09-16
PE20080925A1 (es)	2008-09-04
JP2010504301A (ja)	2010-02-12
DE602007011645D1 (de)	2011-02-10
US20100035917A1 (en)	2010-02-11
US20080176891A1 (en)	2008-07-24
UY30600A1 (es)	2008-05-02

Legal Events

Date	Code	Title	Description
2011-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE493411T1 (de)	2011-01-15	Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer
LTPA2020501I1 (lt)	2020-02-10	Pakeistieji enaminokarbonilo junginiai
ATE490254T1 (de)	2010-12-15	Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer
ATE513831T1 (de)	2011-07-15	Pyridinä3,4-büpyrazinone
CR10653A (es)	2009-04-03	Compuestos de isoindolina 5-substituidos
ATE510825T1 (de)	2011-06-15	Acylaminopyrazole als fgfr-inhibitoren
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
FR2909857B1 (fr)	2009-03-06	Endovalve.
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
ATE524477T1 (de)	2011-09-15	Aziridinylepothilonverbindungen
DE602007012130D1 (de)	2011-03-03	Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
CR10353A (es)	2009-01-09	Nuevos compuestos.
BRPI0716325A2 (pt)	2014-03-04	Composição antimicrobianas
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
ATE467623T1 (de)	2010-05-15	Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
ATE545417T1 (de)	2012-03-15	Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
ATE452132T1 (de)	2010-01-15	Benzimidazolthiophenverbindungen als plk- inhibitoren
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
BRPI0814748A2 (pt)	2015-03-03	Compostos de alditóis substituídos, composições e métodos
ATE495153T1 (de)	2011-01-15	Arylsulfonylpyrrolidine als 5-ht6-inhibitoren
ATE492546T1 (de)	2011-01-15	6-phenyl-1h-imidazoä4,5-cü-pyridin-4- carbonitrilderivate als cathepsin-hemmer
FR2923713B1 (fr)	2010-09-10	Composition reductrice epaissie.
FR2898899B1 (fr)	2012-09-28	Composition photoreticulable
ITCE20060002A1 (it)	2007-09-11	Patok.